Clinical Trial: Use of Hydrogen Sulphide Donor (N-acetyl Cysteine) in Cases With Acute Ischemic Stroke

U.S., Aug. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07749287) titled 'Use of Hydrogen Sulphide Donor (N-acetyl Cysteine) in Cases With Acute Ischemic Stroke' on July 13.

Brief Summary: 1. Clarify novel systemic and local inflammatory mechanisms underlying the cross talk between brain and heart ischemic states,

2. Investigate the new aspects of NAC beyond traditional therapy, in cerebral and myocardial ischemic conditions, both in animal models and clinical cases.

Study Start Date: June 01, 2021

Study Type: INTERVENTIONAL

Condition: Ischemic Cerebral Infarction

Intervention: DRUG: N Acetyl cysteine 600mg

* NAC was administered in a dose of 600 mg, every 8 hours, for 3 consecutive days, either th...